Feline Cushing Syndrome: Diagnosis and Management

Feline hyperadrenocorticism, also known as Cushing syndrome, is a rare endocrine disorder in cats characterized by chronic excessive cortisol production. This condition presents distinct diagnostic and management challenges compared to canine Cushing syndrome. Veterinarians must recognize the unique clinical features, select appropriate diagnostic tests, and implement treatment strategies tailored to the individual cat's underlying pathology. This article provides evidence-based guidance for diagnosing and managing feline Cushing syndrome, with emphasis on practical clinical decision-making.

At a Glance

Pathophysiology and Etiology

Feline hyperadrenocorticism results from chronic excessive cortisol secretion by the adrenal cortex. The condition is classified as pituitary-dependent (PDH) when excessive adrenocorticotropic hormone (ACTH) secretion from a pituitary tumor drives adrenal cortisol production, or adrenal-dependent (ADH) when a functional adrenal tumor autonomously secretes cortisol. Pituitary tumors in cats are most commonly corticotroph adenomas, as described in the veterinary literature on pituitary tumour types in dogs and cats (PubMed, 2021). Adrenal tumors may be adenomas or carcinomas.

The pathophysiology of feline Cushing syndrome differs from dogs in several important respects. Cats with PDH often have larger pituitary tumors at diagnosis compared to dogs, and these tumors may cause neurological signs. A case study documented a cat with a pituitary macroadenoma measuring 18.0 mm on magnetic resonance imaging, which caused behavioral changes including irritation, prowling, and tumbling (Journal of Veterinary Medical Science, 2022). The concurrent development of diabetes mellitus is common in feline hyperadrenocorticism, as cortisol antagonizes insulin action and promotes gluconeogenesis.

Iatrogenic Cushing syndrome can occur in cats receiving exogenous corticosteroids for treatment of other conditions. This form resolves with discontinuation of the corticosteroid medication, but withdrawal must be gradual to avoid adrenal insufficiency.

Clinical Presentation and Recognition

Common Clinical Signs

Feline Cushing syndrome produces a characteristic but variable clinical picture. The most frequently reported signs include polydipsia and polyuria, which often develop secondary to cortisol-induced insulin resistance and diabetes mellitus. A pot-bellied appearance results from muscle wasting and redistribution of body fat. Hepatomegaly is common due to glycogen accumulation in the liver.

Cutaneous manifestations are particularly prominent in cats. Fragile skin that tears easily with minimal trauma is a hallmark finding. Affected cats may develop skin lacerations, hematomas, and poor wound healing. Alopecia, especially on the trunk and flanks, occurs in many cases. The skin may appear thin and atrophic, with visible subcutaneous blood vessels. A case report described acquired skin fragility syndrome and diabetes mellitus secondary to hyperadrenocorticism in a cat (Acta Scientiae Veterinariae, 2018).

Other clinical signs include muscle weakness, lethargy, and recurrent infections. Some cats exhibit behavioral changes such as increased irritability or restlessness, particularly when pituitary macroadenomas are present. The clinical case review of feline Cushing syndrome noted that neurological signs including circling, head pressing, and seizures may develop with large pituitary tumors (Kleintierpraxis, 2019).

Concurrent Diabetes Mellitus

Diabetes mellitus is a common comorbidity in cats with hyperadrenocorticism. The cortisol excess induces insulin resistance, making glycemic control difficult. Cats with poorly regulated diabetes mellitus despite adequate insulin doses should be evaluated for concurrent Cushing syndrome. The presence of both conditions complicates management, as treating the hyperadrenocorticism may improve diabetic control or even lead to diabetic remission.

Physical Examination Findings

A thorough physical examination should assess for:

• Thin, fragile skin that tears easily
• Alopecia, particularly on the trunk
• Pot-bellied appearance
• Hepatomegaly
• Muscle wasting, especially over the epaxial muscles
• Poor coat quality
• Evidence of recurrent infections (dermatitis, urinary tract infections)
• Neurological abnormalities if pituitary macroadenoma is present

Diagnostic Approach

Initial Laboratory Evaluation

The diagnostic workup begins with routine laboratory tests. Complete blood count may reveal a stress leukogram with neutrophilia, lymphopenia, and eosinopenia. Serum biochemistry often shows elevated liver enzymes, particularly alanine aminotransferase and alkaline phosphatase. Hyperglycemia is common, and fructosamine measurement helps assess long-term glycemic control. Urinalysis may reveal glucosuria, proteinuria, or evidence of urinary tract infection.

Endocrine Testing

ACTH Stimulation Test

The ACTH stimulation test is a first-line screening test for feline hyperadrenocorticism. The test involves measuring baseline serum cortisol, administering synthetic ACTH, and measuring post-stimulation cortisol at 60 minutes. Interpretation requires careful consideration, as the test has variable sensitivity in cats. The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines provide recommendations for test protocols and interpretation (Journal of the American Animal Hospital Association, 2023).

Limitations of the ACTH stimulation test include:

• Lower sensitivity compared to the low-dose dexamethasone suppression test
• False negatives can occur, particularly in cats with ADH
• Stress from venipuncture can elevate baseline cortisol
• Results may be affected by concurrent illness or medications

Low-Dose Dexamethasone Suppression Test

The low-dose dexamethasone suppression test is considered more sensitive than the ACTH stimulation test for diagnosing feline hyperadrenocorticism. The protocol involves measuring baseline cortisol, administering dexamethasone intravenously, and measuring cortisol at 4 and 8 hours post-injection. In normal cats, cortisol should suppress to low levels. Failure to suppress indicates hyperadrenocorticism.

This test can also help differentiate PDH from ADH. In PDH, cortisol may suppress partially or show a paradoxical increase at 8 hours. In ADH, cortisol typically fails to suppress at any time point. However, overlap between patterns occurs, and additional testing is often needed for definitive differentiation.

Urine Cortisol-to-Creatinine Ratio

The urine cortisol-to-creatinine ratio is a useful screening test that can be performed on a single urine sample collected at home to minimize stress. An elevated ratio supports the diagnosis of hyperadrenocorticism but does not differentiate PDH from ADH. False positives can occur with stress, illness, or non-adrenal disease. A normal ratio makes hyperadrenocorticism unlikely.

Imaging Studies

Abdominal Ultrasound

Abdominal ultrasound is essential for evaluating the adrenal glands. In PDH, both adrenal glands appear symmetrically enlarged with normal shape. In ADH, one adrenal gland is enlarged (often with a mass), while the contralateral gland may be small or normal due to suppression of ACTH. Ultrasound also assesses for metastatic disease if adrenal carcinoma is suspected.

The use of diagnostic computerized tomography and radiation therapy in canine and feline hyperadrenocorticism has been described in the veterinary literature (Problems in Veterinary Medicine, 1990). CT provides detailed anatomical information about adrenal size, shape, and symmetry, and is superior to ultrasound for detecting small adrenal masses.

Pituitary Imaging

Advanced imaging of the pituitary gland is indicated when PDH is suspected, particularly if neurological signs are present. Magnetic resonance imaging is the preferred modality for evaluating pituitary size and detecting macroadenomas. CT can also identify pituitary enlargement but provides less soft tissue detail.

Pituitary macroadenomas in cats can be large at diagnosis. The case study of successful treatment of feline hyperadrenocorticism with pituitary macroadenoma using radiation therapy documented a tumor measuring 18.0 mm (Journal of Veterinary Medical Science, 2022). Pituitary tumors larger than 10 mm are considered macroadenomas and may cause neurological signs.

Differentiating PDH from ADH

Differentiation between PDH and ADH is critical for treatment planning. The following table summarizes the diagnostic approach:

Endogenous ACTH measurement is particularly useful. In PDH, ACTH levels are normal to elevated. In ADH, ACTH is suppressed due to negative feedback from autonomous cortisol production. The case study reported endogenous ACTH levels greater than 2,500 pg/mL in a cat with PDH and pituitary macroadenoma (Journal of Veterinary Medical Science, 2022).

Treatment Options

Medical Management with Trilostane

Trilostane is the primary medical treatment for feline hyperadrenocorticism. It inhibits 3-beta-hydroxysteroid dehydrogenase, blocking cortisol synthesis. Trilostane is used for both PDH and ADH, particularly when surgery is not feasible or declined by the owner.

Treatment with trilostane requires careful monitoring. The starting dose should be conservative, and dose adjustments are made based on clinical response and ACTH stimulation test results. The goal is to normalize cortisol production without causing adrenal insufficiency. Clinical signs of adequate control include improved skin condition, reduced polydipsia and polyuria, and better glycemic control in diabetic cats.

Limitations of trilostane therapy include:

• Variable response, some cats do not achieve adequate control
• Side effects including vomiting, diarrhea, lethargy, and anorexia
• Risk of hypoadrenocorticism if overdosed
• Does not address the underlying pituitary tumor
• Neurological signs from pituitary macroadenoma may not improve

In the case study of a cat with pituitary macroadenoma, trilostane treatment at 5-10 mg per head daily did not resolve clinical signs, and insulin and trilostane were discontinued after radiation therapy began (Journal of Veterinary Medical Science, 2022).

Surgical Treatment

Adrenalectomy

Adrenalectomy is the treatment of choice for ADH caused by a unilateral adrenal tumor. The procedure requires advanced surgical expertise and careful perioperative management. Preoperative stabilization with trilostane may be needed to reduce surgical risk. Postoperative complications include hypoadrenocorticism if the contralateral adrenal gland is atrophied, pancreatitis, and wound dehiscence.

Hypophysectomy

Hypophysectomy is an option for PDH in cats, but it is technically challenging and available only at specialized referral centers. The procedure involves surgical removal of the pituitary tumor. Success depends on tumor size and location. Postoperative management includes lifelong hormone replacement therapy for multiple pituitary hormone deficiencies.

Radiation Therapy

Radiation therapy is indicated for pituitary macroadenomas causing neurological signs or when surgery is not possible. The case study demonstrated that radiation therapy (4 Gy in 12 fractions) led to decreased pituitary tumor size from 18.0 mm to 10.7 mm by day 301, with remission of neurological and dermatological signs (Journal of Veterinary Medical Science, 2022). Insulin and trilostane treatment were discontinued by day 86 after radiation therapy began.

Radiation therapy may also be used for adrenal tumors that are not surgically resectable. The use of diagnostic computerized tomography and radiation therapy in canine and feline hyperadrenocorticism has been described (Problems in Veterinary Medicine, 1990).

Management of Concurrent Diabetes Mellitus

Cats with concurrent diabetes mellitus require careful insulin management. Insulin requirements may decrease as hyperadrenocorticism is treated. Blood glucose monitoring is essential to prevent hypoglycemia. Diabetic remission is possible if the hyperadrenocorticism is successfully controlled.

Monitoring and Follow-Up

Clinical Monitoring

Regular assessment of clinical signs is essential for evaluating treatment response. Key parameters to monitor include:

• Skin condition and hair regrowth
• Body weight and muscle condition
• Water intake and urine output
• Appetite and energy level
• Neurological status if pituitary tumor present

Laboratory Monitoring

ACTH stimulation tests should be performed periodically to assess cortisol suppression and guide trilostane dose adjustments. The frequency of testing depends on clinical response and stability. Serum biochemistry and electrolytes should be monitored to detect adverse effects of treatment.

For diabetic cats, serial blood glucose curves and fructosamine measurements help assess glycemic control. Insulin doses may need adjustment as cortisol levels normalize.

Imaging Follow-Up

Repeat abdominal ultrasound or CT may be indicated to monitor adrenal tumor size or assess for recurrence after adrenalectomy. Pituitary imaging should be repeated if neurological signs develop or worsen.

Common Failure Patterns

Diagnostic Challenges

Feline hyperadrenocorticism is frequently misdiagnosed or diagnosed late due to its rarity and variable presentation. Common diagnostic failures include:

• Failure to consider Cushing syndrome in cats with poorly controlled diabetes
• Reliance on a single diagnostic test with low sensitivity
• Misinterpretation of ACTH stimulation test results due to stress effects
• Overlooking iatrogenic Cushing from corticosteroid administration

Treatment Failures

Treatment failures may occur for several reasons:

• Inadequate trilostane dose or poor owner compliance
• Progression of pituitary tumor causing neurological signs
• Development of adrenal insufficiency from overtreatment
• Persistent diabetes mellitus despite cortisol control
• Recurrence after adrenalectomy due to metastatic disease

Owner-Related Factors

Owner factors that contribute to treatment failure include:

• Difficulty administering oral medication to cats
• Financial constraints limiting diagnostic testing or treatment
• Reluctance to pursue advanced imaging or referral
• Poor understanding of the chronic nature of the disease

Quality of Life Considerations

Feline hyperadrenocorticism significantly impacts quality of life. The chronic cortisol excess causes physical discomfort from fragile skin, muscle wasting, and recurrent infections. Concurrent diabetes mellitus adds additional management burden. Neurological signs from pituitary macroadenomas can be distressing for both cat and owner.

Quality of life in Cushing syndrome has been studied in human medicine, and similar considerations apply to veterinary patients (Best Practice & Research Clinical Endocrinology & Metabolism, 2021). Veterinarians should discuss quality of life with owners and consider euthanasia when treatment fails to provide adequate relief.

Professional Escalation Criteria

Veterinarians should consider referral to a veterinary internal medicine specialist or veterinary endocrinologist in the following situations:

• Suspected hyperadrenocorticism but inconclusive diagnostic test results
• Need for advanced imaging (CT, MRI) for pituitary or adrenal evaluation
• Consideration of surgical treatment (adrenalectomy, hypophysectomy)
• Radiation therapy for pituitary macroadenoma
• Poor response to trilostane therapy
• Development of neurological signs
• Complex management of concurrent diabetes mellitus
• Suspected adrenal carcinoma with potential for metastasis

Practical Decision Framework for Monitoring Trilostane Response and Adjusting Therapy in Feline Hyperadrenocorticism

Medical management with trilostane requires a structured monitoring protocol to balance efficacy against the risk of hypoadrenocorticism. Unlike canine patients where ACTH stimulation test targets are well established, feline response patterns show greater individual variation. This section provides a practical decision framework for veterinarians managing cats on trilostane therapy, including a record system, troubleshooting methods for common complications, and clear escalation criteria.

Establishing a Baseline Before Trilostane Initiation

Before starting trilostane, document the following baseline parameters to enable objective assessment of treatment response:

• Serum cortisol concentration (baseline and ACTH-stimulated)
• Serum biochemistry panel including electrolytes (sodium, potassium)
• Blood glucose concentration and fructosamine if diabetic
• Body weight and body condition score
• Water intake measured over 24 hours (normal feline intake is approximately 20-40 mL/kg/day)
• Urine output estimation based on litter box monitoring
• Skin condition scoring using a standardized system (0 = normal, 1 = mild thinning, 2 = moderate fragility with occasional tearing, 3 = severe fragility with frequent tearing)
• Photographic documentation of alopecia and skin lesions

The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines emphasize that baseline documentation improves the ability to detect subtle changes during therapy (Journal of the American Animal Hospital Association, 2023). Without objective baseline measurements, clinicians may miss early indicators of inadequate response or overtreatment.

Trilostane Dosing Protocol and Initial Monitoring Schedule

Trilostane is typically initiated at 1-2 mg/kg once daily in cats. The starting dose should be conservative because feline metabolism of trilostane differs from dogs and some cats show marked sensitivity. Administer the medication with food to improve absorption and reduce gastrointestinal side effects.

The initial monitoring schedule follows this timeline:

• Day 0: Baseline ACTH stimulation test, biochemistry, electrolytes, blood glucose
• Day 7-10: Recheck ACTH stimulation test 4-6 hours after trilostane administration
• Day 14: Clinical assessment, owner interview, body weight
• Day 30: ACTH stimulation test, biochemistry, electrolytes
• Day 60: Full re-evaluation including imaging if indicated
• Every 3-6 months thereafter: ACTH stimulation test, biochemistry, electrolytes

The ACTH stimulation test should be performed 4-6 hours after the morning trilostane dose to capture peak drug effect. Post-ACTH cortisol concentrations between 2-5 mcg/dL (55-138 nmol/L) are generally considered therapeutic targets, though individual targets may vary based on clinical response. The case study of a cat with pituitary macroadenoma receiving trilostane at 5-10 mg per head daily showed that clinical signs did not resolve despite treatment, highlighting the need for objective monitoring instead of relying solely on clinical impression (Journal of Veterinary Medical Science, 2022).

Record System for Tracking Treatment Response

A structured record system improves consistency in monitoring and facilitates early detection of complications. The following template can be adapted for clinical use:

Trilostane Monitoring Record

Maintain a separate log for diabetic cats that includes insulin type, dose, frequency, blood glucose curve results, and fructosamine values. The interaction between trilostane and insulin therapy requires close coordination because cortisol reduction often decreases insulin requirements.

Interpreting ACTH Stimulation Test Results During Therapy

Post-ACTH cortisol concentrations guide dose adjustments. The following interpretation framework applies to feline patients:

Post-ACTH Cortisol Below 2 mcg/dL (55 nmol/L): Indicates excessive cortisol suppression. The cat is at risk for hypoadrenocorticism. Reduce trilostane dose by 25-50% and recheck ACTH stimulation test in 7-10 days. If the cat shows clinical signs of hypoadrenocorticism (lethargy, vomiting, diarrhea, collapse), discontinue trilostane temporarily and provide supportive care including fluid therapy and glucocorticoid supplementation if needed.

Post-ACTH Cortisol 2-5 mcg/dL (55-138 nmol/L): Indicates adequate cortisol suppression. Continue current dose if clinical signs are improving. If clinical signs persist despite adequate cortisol suppression, investigate other causes such as concurrent diabetes mellitus, inadequate duration of action, or progression of pituitary tumor.

Post-ACTH Cortisol 5-10 mcg/dL (138-276 nmol/L): Indicates partial suppression. Consider increasing trilostane dose by 25-50% if clinical signs are not adequately controlled. Recheck ACTH stimulation test in 7-10 days after dose adjustment.

Post-ACTH Cortisol Above 10 mcg/dL (276 nmol/L): Indicates inadequate suppression. Increase trilostane dose by 50-100% or consider twice-daily dosing if the drug effect does not last 24 hours. Recheck ACTH stimulation test in 7-10 days.

The feline adrenal disorders literature notes that cats may require higher trilostane doses on a mg/kg basis compared to dogs, and some cats benefit from twice-daily administration (Clinical Techniques in Small Animal Practice, 2007). If a cat fails to show adequate cortisol suppression despite escalating doses, consider poor owner compliance, drug malabsorption, or misdiagnosis.

Troubleshooting Common Complications

Hypoadrenocorticism from Overtreatment

Clinical signs of hypoadrenocorticism include lethargy, weakness, anorexia, vomiting, diarrhea, and collapse. Electrolyte abnormalities may include hyponatremia and hyperkalemia, though these are less consistent in cats compared to dogs.

Management protocol for suspected hypoadrenocorticism:

1. Discontinue trilostane immediately
2. Obtain blood for STAT electrolytes and cortisol measurement
3. Administer intravenous fluids (0.9% sodium chloride) at shock rates if hypovolemic
4. Administer dexamethasone sodium phosphate (0.5-1 mg/kg IV) for glucocorticoid support
5. Monitor electrolytes every 6-12 hours until normalized
6. Once stabilized, restart trilostane at 50% of the previous dose after 3-7 days
7. Recheck ACTH stimulation test 7-10 days after restarting therapy

The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines recommend that veterinarians educate owners about signs of hypoadrenocorticism and provide emergency contact instructions (Journal of the American Animal Hospital Association, 2023). Owners should be advised to seek immediate veterinary care if their cat shows vomiting, diarrhea, or collapse while on trilostane.

Persistent Clinical Signs Despite Adequate Cortisol Suppression

Some cats show persistent clinical signs even when post-ACTH cortisol concentrations fall within the therapeutic range. Common causes include:

• Concurrent diabetes mellitus with poor glycemic control: Cortisol reduction may not fully reverse insulin resistance. Optimize insulin therapy and monitor blood glucose curves.
• Progression of pituitary tumor: Large macroadenomas may cause neurological signs that do not improve with cortisol reduction. The case study documented that neurological signs including irritation, prowling, and tumbling persisted despite trilostane therapy until radiation therapy was administered (Journal of Veterinary Medical Science, 2022).
• Irreversible skin damage: Chronic cortisol excess causes structural changes in collagen and elastin that may not fully reverse. Skin fragility may persist even after cortisol normalization.
• Concurrent disease: Hyperadrenocorticism predisposes to urinary tract infections, pancreatitis, and other comorbidities that cause persistent clinical signs.

When clinical signs persist despite adequate cortisol suppression, perform a thorough re-evaluation including complete blood count, serum biochemistry, urinalysis with culture, abdominal ultrasound, and pituitary imaging if not previously performed.

Gastrointestinal Side Effects

Trilostane can cause vomiting, diarrhea, and anorexia in some cats. Management strategies include:

• Administering the medication with a small meal
• Dividing the daily dose into two smaller doses
• Reducing the dose temporarily and gradually increasing
• Adding a gastrointestinal protectant such as famotidine or omeprazole
• Switching to a different formulation if available

If gastrointestinal side effects are severe or persistent, consider alternative treatment options such as adrenalectomy or radiation therapy.

Monitoring Concurrent Diabetes Mellitus

Cats with concurrent diabetes mellitus require particularly close monitoring during trilostane therapy. Cortisol reduction typically improves insulin sensitivity, which can lead to hypoglycemia if insulin doses are not adjusted promptly.

Monitoring protocol for diabetic cats on trilostane:

• Day 0: Blood glucose curve, fructosamine, insulin dose documentation
• Day 3-5: Owner performs blood glucose curve at home if possible
• Day 7: Recheck blood glucose curve and adjust insulin dose as needed
• Day 14: Blood glucose curve, fructosamine, clinical assessment
• Day 30: Full re-evaluation including ACTH stimulation test
• Monthly thereafter: Blood glucose curve and fructosamine until stable

Insulin dose adjustments should be made proactively. A common approach is to reduce the insulin dose by 25% when trilostane is initiated, then adjust based on blood glucose curves. Some cats achieve diabetic remission and may no longer require insulin therapy. The case study reported that insulin treatment was discontinued by day 86 after radiation therapy began, indicating that successful treatment of hyperadrenocorticism can lead to diabetic remission (Journal of Veterinary Medical Science, 2022).

When to Consider Twice-Daily Trilostane Dosing

Some cats show inadequate cortisol suppression at the end of the 24-hour dosing interval, even when post-ACTH cortisol concentrations measured 4-6 hours after dosing are within the therapeutic range. Indicators that twice-daily dosing may be beneficial include:

• Clinical signs (polydipsia, polyuria) return in the evening or early morning
• Post-ACTH cortisol measured 12 hours after dosing is above 10 mcg/dL
• The cat requires high doses (greater than 3 mg/kg once daily) to achieve adequate suppression
• Poor glycemic control in diabetic cats despite adequate morning cortisol suppression

When switching to twice-daily dosing, divide the total daily dose into two equal doses given approximately 12 hours apart. Recheck ACTH stimulation test 4-6 hours after the morning dose and again 4-6 hours after the evening dose to assess the full 24-hour cortisol profile.

Long-Term Monitoring and Dose Adjustments

Trilostane requirements may change over time. Factors that influence long-term dosing include:

• Progression or regression of the underlying pituitary or adrenal tumor
• Changes in body weight
• Development of concurrent disease
• Changes in diet or medication administration

Perform ACTH stimulation testing every 3-6 months in stable patients. Increase testing frequency if clinical signs recur or if the cat develops new medical problems. The feline adrenal disorders literature indicates that some cats require dose increases over time, while others maintain stable doses for extended periods (Clinical Techniques in Small Animal Practice, 2007).

Escalation Criteria for Treatment Failure

When trilostane therapy fails to achieve adequate clinical control despite appropriate dosing and monitoring, consider the following escalation options:

1. Referral for advanced imaging: If pituitary imaging has not been performed, MRI or CT can identify macroadenomas that may benefit from radiation therapy. The case study demonstrated that radiation therapy (4 Gy in 12 fractions) led to decreased pituitary tumor size from 18.0 mm to 10.7 mm with remission of neurological and dermatological signs (Journal of Veterinary Medical Science, 2022).

2. Referral for surgical consultation: Adrenalectomy is the treatment of choice for ADH caused by unilateral adrenal tumors. Hypophysectomy is an option for PDH at specialized referral centers.

3. Consider radiation therapy: Radiation therapy is indicated for pituitary macroadenomas causing neurological signs or when surgery is not possible. The use of diagnostic computerized tomography and radiation therapy in canine and feline hyperadrenocorticism has been described in the veterinary literature (Problems in Veterinary Medicine, 1990).

4. Re-evaluate the diagnosis: If a cat fails to respond to trilostane despite adequate cortisol suppression, reconsider the diagnosis. Conditions that mimic hyperadrenocorticism include diabetes mellitus alone, acromegaly, and iatrogenic Cushing syndrome from exogenous corticosteroids.

Owner Communication and Compliance Strategies

Successful trilostane therapy depends on owner compliance. Common barriers include difficulty medicating cats, financial constraints, and misunderstanding of the chronic nature of the disease.

Practical strategies for improving owner compliance:

• Demonstrate pill administration techniques during clinic visits
• Provide written instructions for medication timing and monitoring
• Discuss the expected timeline for clinical improvement (skin changes may take 2-4 months, hair regrowth may take 3-6 months)
• Explain the importance of regular recheck appointments
• Discuss the cost of ongoing monitoring and treatment upfront
• Provide emergency contact information for after-hours complications

The quality of life in Cushing syndrome literature emphasizes that owner education and support improve treatment outcomes and reduce the risk of complications (Best Practice & Research Clinical Endocrinology & Metabolism, 2021). Owners who understand the rationale for monitoring are more likely to comply with recheck appointments and report concerning signs promptly.

Summary of Practical Decision Points

This decision framework provides a structured approach to trilostane monitoring that reduces the risk of complications and improves treatment outcomes. Veterinarians should adapt these guidelines to individual patient needs and consult with veterinary internal medicine specialists when managing complex cases.

Practical Decision Framework for Monitoring Trilostane Response and Adjusting Therapy in Feline Hyperadrenocorticism

Medical management with trilostane requires a structured monitoring protocol to balance efficacy against the risk of hypoadrenocorticism. Unlike canine patients where ACTH stimulation test targets are well established, feline response patterns show greater individual variation. This section provides a practical decision framework for veterinarians managing cats on trilostane therapy, including a record system, troubleshooting methods for common complications, and clear escalation criteria.

Establishing a Baseline Before Trilostane Initiation

Before starting trilostane, document the following baseline parameters to enable objective assessment of treatment response:

• Serum cortisol concentration (baseline and ACTH-stimulated)
• Serum biochemistry panel including electrolytes (sodium, potassium)
• Blood glucose concentration and fructosamine if diabetic
• Body weight and body condition score
• Water intake measured over 24 hours (normal feline intake is approximately 20-40 mL/kg/day)
• Urine output estimation based on litter box monitoring
• Skin condition scoring using a standardized system (0 = normal, 1 = mild thinning, 2 = moderate fragility with occasional tearing, 3 = severe fragility with frequent tearing)
• Photographic documentation of alopecia and skin lesions

The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines emphasize that baseline documentation improves the ability to detect subtle changes during therapy (Journal of the American Animal Hospital Association, 2023). Without objective baseline measurements, clinicians may miss early indicators of inadequate response or overtreatment.

Trilostane Dosing Protocol and Initial Monitoring Schedule

Trilostane is typically initiated at 1-2 mg/kg once daily in cats. The starting dose should be conservative because feline metabolism of trilostane differs from dogs and some cats show marked sensitivity. Administer the medication with food to improve absorption and reduce gastrointestinal side effects.

The initial monitoring schedule follows this timeline:

• Day 0: Baseline ACTH stimulation test, biochemistry, electrolytes, blood glucose
• Day 7-10: Recheck ACTH stimulation test 4-6 hours after trilostane administration
• Day 14: Clinical assessment, owner interview, body weight
• Day 30: ACTH stimulation test, biochemistry, electrolytes
• Day 60: Full re-evaluation including imaging if indicated
• Every 3-6 months thereafter: ACTH stimulation test, biochemistry, electrolytes

The ACTH stimulation test should be performed 4-6 hours after the morning trilostane dose to capture peak drug effect. Post-ACTH cortisol concentrations between 2-5 mcg/dL (55-138 nmol/L) are generally considered therapeutic targets, though individual targets may vary based on clinical response. The case study of a cat with pituitary macroadenoma receiving trilostane at 5-10 mg per head daily showed that clinical signs did not resolve despite treatment, highlighting the need for objective monitoring instead of relying solely on clinical impression (Journal of Veterinary Medical Science, 2022).

Record System for Tracking Treatment Response

A structured record system improves consistency in monitoring and facilitates early detection of complications. The following template can be adapted for clinical use:

Trilostane Monitoring Record

Maintain a separate log for diabetic cats that includes insulin type, dose, frequency, blood glucose curve results, and fructosamine values. The interaction between trilostane and insulin therapy requires close coordination because cortisol reduction often decreases insulin requirements.

Interpreting ACTH Stimulation Test Results During Therapy

Post-ACTH cortisol concentrations guide dose adjustments. The following interpretation framework applies to feline patients:

Post-ACTH Cortisol Below 2 mcg/dL (55 nmol/L): Indicates excessive cortisol suppression. The cat is at risk for hypoadrenocorticism. Reduce trilostane dose by 25-50% and recheck ACTH stimulation test in 7-10 days. If the cat shows clinical signs of hypoadrenocorticism (lethargy, vomiting, diarrhea, collapse), discontinue trilostane temporarily and provide supportive care including fluid therapy and glucocorticoid supplementation if needed.

Post-ACTH Cortisol 2-5 mcg/dL (55-138 nmol/L): Indicates adequate cortisol suppression. Continue current dose if clinical signs are improving. If clinical signs persist despite adequate cortisol suppression, investigate other causes such as concurrent diabetes mellitus, inadequate duration of action, or progression of pituitary tumor.

Post-ACTH Cortisol 5-10 mcg/dL (138-276 nmol/L): Indicates partial suppression. Consider increasing trilostane dose by 25-50% if clinical signs are not adequately controlled. Recheck ACTH stimulation test in 7-10 days after dose adjustment.

Post-ACTH Cortisol Above 10 mcg/dL (276 nmol/L): Indicates inadequate suppression. Increase trilostane dose by 50-100% or consider twice-daily dosing if the drug effect does not last 24 hours. Recheck ACTH stimulation test in 7-10 days.

The feline adrenal disorders literature notes that cats may require higher trilostane doses on a mg/kg basis compared to dogs, and some cats benefit from twice-daily administration (Clinical Techniques in Small Animal Practice, 2007). If a cat fails to show adequate cortisol suppression despite escalating doses, consider poor owner compliance, drug malabsorption, or misdiagnosis.

Troubleshooting Common Complications

Hypoadrenocorticism from Overtreatment

Clinical signs of hypoadrenocorticism include lethargy, weakness, anorexia, vomiting, diarrhea, and collapse. Electrolyte abnormalities may include hyponatremia and hyperkalemia, though these are less consistent in cats compared to dogs.

Management protocol for suspected hypoadrenocorticism:

1. Discontinue trilostane immediately
2. Obtain blood for STAT electrolytes and cortisol measurement
3. Administer intravenous fluids (0.9% sodium chloride) at shock rates if hypovolemic
4. Administer dexamethasone sodium phosphate (0.5-1 mg/kg IV) for glucocorticoid support
5. Monitor electrolytes every 6-12 hours until normalized
6. Once stabilized, restart trilostane at 50% of the previous dose after 3-7 days
7. Recheck ACTH stimulation test 7-10 days after restarting therapy

The 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines recommend that veterinarians educate owners about signs of hypoadrenocorticism and provide emergency contact instructions (Journal of the American Animal Hospital Association, 2023). Owners should be advised to seek immediate veterinary care if their cat shows vomiting, diarrhea, or collapse while on trilostane.

Persistent Clinical Signs Despite Adequate Cortisol Suppression

Some cats show persistent clinical signs even when post-ACTH cortisol concentrations fall within the therapeutic range. Common causes include:

• Concurrent diabetes mellitus with poor glycemic control: Cortisol reduction may not fully reverse insulin resistance. Optimize insulin therapy and monitor blood glucose curves.
• Progression of pituitary tumor: Large macroadenomas may cause neurological signs that do not improve with cortisol reduction. The case study documented that neurological signs including irritation, prowling, and tumbling persisted despite trilostane therapy until radiation therapy was administered (Journal of Veterinary Medical Science, 2022).
• Irreversible skin damage: Chronic cortisol excess causes structural changes in collagen and elastin that may not fully reverse. Skin fragility may persist even after cortisol normalization.
• Concurrent disease: Hyperadrenocorticism predisposes to urinary tract infections, pancreatitis, and other comorbidities that cause persistent clinical signs.

When clinical signs persist despite adequate cortisol suppression, perform a thorough re-evaluation including complete blood count, serum biochemistry, urinalysis with culture, abdominal ultrasound, and pituitary imaging if not previously performed.

Gastrointestinal Side Effects

Trilostane can cause vomiting, diarrhea, and anorexia in some cats. Management strategies include:

• Administering the medication with a small meal
• Dividing the daily dose into two smaller doses
• Reducing the dose temporarily and gradually increasing
• Adding a gastrointestinal protectant such as famotidine or omeprazole
• Switching to a different formulation if available

If gastrointestinal side effects are severe or persistent, consider alternative treatment options such as adrenalectomy or radiation therapy.

Monitoring Concurrent Diabetes Mellitus

Cats with concurrent diabetes mellitus require particularly close monitoring during trilostane therapy. Cortisol reduction typically improves insulin sensitivity, which can lead to hypoglycemia if insulin doses are not adjusted promptly.

Monitoring protocol for diabetic cats on trilostane:

• Day 0: Blood glucose curve, fructosamine, insulin dose documentation
• Day 3-5: Owner performs blood glucose curve at home if possible
• Day 7: Recheck blood glucose curve and adjust insulin dose as needed
• Day 14: Blood glucose curve, fructosamine, clinical assessment
• Day 30: Full re-evaluation including ACTH stimulation test
• Monthly thereafter: Blood glucose curve and fructosamine until stable

Insulin dose adjustments should be made proactively. A common approach is to reduce the insulin dose by 25% when trilostane is initiated, then adjust based on blood glucose curves. Some cats achieve diabetic remission and may no longer require insulin therapy. The case study reported that insulin treatment was discontinued by day 86 after radiation therapy began, indicating that successful treatment of hyperadrenocorticism can lead to diabetic remission (Journal of Veterinary Medical Science, 2022).

When to Consider Twice-Daily Trilostane Dosing

Some cats show inadequate cortisol suppression at the end of the 24-hour dosing interval, even when post-ACTH cortisol concentrations measured 4-6 hours after dosing are within the therapeutic range. Indicators that twice-daily dosing may be beneficial include:

• Clinical signs (polydipsia, polyuria) return in the evening or early morning
• Post-ACTH cortisol measured 12 hours after dosing is above 10 mcg/dL
• The cat requires high doses (greater than 3 mg/kg once daily) to achieve adequate suppression
• Poor glycemic control in diabetic cats despite adequate morning cortisol suppression

When switching to twice-daily dosing, divide the total daily dose into two equal doses given approximately 12 hours apart. Recheck ACTH stimulation test 4-6 hours after the morning dose and again 4-6 hours after the evening dose to assess the full 24-hour cortisol profile.

Long-Term Monitoring and Dose Adjustments

Trilostane requirements may change over time. Factors that influence long-term dosing include:

• Progression or regression of the underlying pituitary or adrenal tumor
• Changes in body weight
• Development of concurrent disease
• Changes in diet or medication administration

Perform ACTH stimulation testing every 3-6 months in stable patients. Increase testing frequency if clinical signs recur or if the cat develops new medical problems. The feline adrenal disorders literature indicates that some cats require dose increases over time, while others maintain stable doses for extended periods (Clinical Techniques in Small Animal Practice, 2007).

Escalation Criteria for Treatment Failure

When trilostane therapy fails to achieve adequate clinical control despite appropriate dosing and monitoring, consider the following escalation options:

1. Referral for advanced imaging: If pituitary imaging has not been performed, MRI or CT can identify macroadenomas that may benefit from radiation therapy. The case study demonstrated that radiation therapy (4 Gy in 12 fractions) led to decreased pituitary tumor size from 18.0 mm to 10.7 mm with remission of neurological and dermatological signs (Journal of Veterinary Medical Science, 2022).

2. Referral for surgical consultation: Adrenalectomy is the treatment of choice for ADH caused by unilateral adrenal tumors. Hypophysectomy is an option for PDH at specialized referral centers.

3. Consider radiation therapy: Radiation therapy is indicated for pituitary macroadenomas causing neurological signs or when surgery is not possible. The use of diagnostic computerized tomography and radiation therapy in canine and feline hyperadrenocorticism has been described in the veterinary literature (Problems in Veterinary Medicine, 1990).

4. Re-evaluate the diagnosis: If a cat fails to respond to trilostane despite adequate cortisol suppression, reconsider the diagnosis. Conditions that mimic hyperadrenocorticism include diabetes mellitus alone, acromegaly, and iatrogenic Cushing syndrome from exogenous corticosteroids.

Owner Communication and Compliance Strategies

Successful trilostane therapy depends on owner compliance. Common barriers include difficulty medicating cats, financial constraints, and misunderstanding of the chronic nature of the disease.

Practical strategies for improving owner compliance:

• Demonstrate pill administration techniques during clinic visits
• Provide written instructions for medication timing and monitoring
• Discuss the expected timeline for clinical improvement (skin changes may take 2-4 months, hair regrowth may take 3-6 months)
• Explain the importance of regular recheck appointments
• Discuss the cost of ongoing monitoring and treatment upfront
• Provide emergency contact information for after-hours complications

The quality of life in Cushing syndrome literature emphasizes that owner education and support improve treatment outcomes and reduce the risk of complications (Best Practice & Research Clinical Endocrinology & Metabolism, 2021). Owners who understand the rationale for monitoring are more likely to comply with recheck appointments and report concerning signs promptly.

Summary of Practical Decision Points

This decision framework provides a structured approach to trilostane monitoring that reduces the risk of complications and improves treatment outcomes. Veterinarians should adapt these guidelines to individual patient needs and consult with veterinary internal medicine specialists when managing complex cases.

Frequently Asked Questions

What is the difference between pituitary-dependent and adrenal-dependent feline Cushing syndrome?

Pituitary-dependent hyperadrenocorticism (PDH) is caused by a pituitary tumor that secretes excessive ACTH, stimulating both adrenal glands to produce cortisol. Adrenal-dependent hyperadrenocorticism (ADH) results from a functional adrenal tumor that autonomously secretes cortisol, suppressing ACTH production. PDH accounts for most cases, while ADH accounts for a smaller proportion. Differentiation requires endocrine testing and imaging studies.

How is feline Cushing syndrome diagnosed?

Diagnosis involves a combination of clinical signs, routine laboratory tests, endocrine testing, and imaging. The low-dose dexamethasone suppression test is considered more sensitive than the ACTH stimulation test. Abdominal ultrasound evaluates adrenal gland size and symmetry. Pituitary imaging with MRI or CT is indicated when PDH is suspected. Endogenous ACTH measurement helps differentiate PDH from ADH.

What are the treatment options for feline Cushing syndrome?

Treatment options include medical management with trilostane, surgical adrenalectomy for ADH, hypophysectomy for PDH, and radiation therapy for pituitary macroadenomas. The choice depends on the underlying cause, tumor size, presence of neurological signs, and owner preferences. Trilostane is the most commonly used medical treatment, but it does not address the underlying pituitary tumor.

Can feline Cushing syndrome be cured?

Cure is possible with surgical removal of an adrenal tumor (adrenalectomy) or pituitary tumor (hypophysectomy). However, these procedures require specialized expertise and carry significant risks. Medical management with trilostane controls clinical signs but does not cure the disease. Radiation therapy can shrink pituitary tumors and improve clinical signs but may not eliminate the tumor entirely.

Is feline Cushing syndrome painful?

The condition itself is not typically painful, but it causes significant discomfort. Fragile skin tears easily, leading to wounds and hematomas. Muscle wasting causes weakness and difficulty jumping. Recurrent infections cause additional discomfort. Large pituitary tumors can cause headaches and neurological signs. Pain management should be addressed as part of comprehensive care.

How does diabetes mellitus affect management of feline Cushing syndrome?

Diabetes mellitus is a common comorbidity that complicates management. Cortisol excess induces insulin resistance, making glycemic control difficult. Treating hyperadrenocorticism often improves diabetic control, and some cats achieve diabetic remission. Close monitoring of blood glucose is essential, and insulin doses may need adjustment as cortisol levels normalize.

What is the prognosis for cats with Cushing syndrome?

Prognosis is guarded to fair and depends on several factors including the underlying cause, tumor size, presence of neurological signs, and response to treatment. Cats with ADH that undergo successful adrenalectomy have a better prognosis. Cats with PDH and large pituitary macroadenomas have a more guarded prognosis. Concurrent diabetes mellitus adds complexity but can be managed.

When should I refer a cat with suspected Cushing syndrome to a specialist?

Referral is recommended when diagnostic test results are inconclusive, advanced imaging is needed, surgical treatment is considered, radiation therapy is indicated, or the cat has a poor response to medical therapy. Cats with neurological signs from pituitary macroadenomas should be referred urgently. Complex cases with concurrent diabetes mellitus may also benefit from specialist management.

Related Veterinary Guides

• Cat
• Clinical Biochemistry Urinalysis
• Hypertrophic Cardiomyopathy In Cats
• Prescription Medicine For Cats
• Sneezing Cat Remedy

References and Further Reading

• www.merckvetmanual.com
• catvets.com
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• 2023 AAHA Selected Endocrinopathies of Dogs and Cats Guidelines.. Journal of the American Animal Hospital Association, 2023.
• Pituitary tumour types in dogs and cats.. Veterinary journal (London, England : 1997), 2021.
• Cushing's syndrome and pregnancy: Clinical presentation and diagnosis.. Vitamins and hormones, 2026.
• Feline adrenal disorders.. Clinical techniques in small animal practice, 2007.
• Quality of life in Cushing's syndrome.. Best practice & research. Clinical endocrinology & metabolism, 2021.
• Endocrine tumors.. The Veterinary clinics of North America. Small animal practice, 1985.
• Successful treatment of feline hyperadrenocorticism with pituitary macroadenoma using radiation therapy: a case study. Journal of Veterinary Medical Science, 2022.
• The use of diagnostic computerized tomography and radiation therapy in canine and feline hyperadrenocorticism.. 1990.
• The use of diagnostic computerized tomography and radiation therapy in canine and feline hyperadrenocorticism.. Problems in veterinary medicine, 1990.
• Feline Cushing's syndrome - Clinical case and review. Kleintierpraxis, 2019.
• Feline cushing's syndrome. Veterinaria, 2014.
• Acquired skin fragility syndrome and diabetes mellitus secondary to hyperadrenocorticism in a cat. Acta Scientiae Veterinariae, 2018.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.